Nitrogen-containing heterocyclic derivative inhibitor as well as preparation method and application thereof
Patent Information
- Application Number
- CN202380071542.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-08-10
- Filing Date
- 2023-10-13
- Publication Date
- 2025-05-16
- Estimated Expiration
- 2043-10-13
AI Technical Summary
Most existing PCSK9 inhibitors are injectable, which has high production costs and high prices. Furthermore, statins have limited effectiveness in lowering low-density lipoprotein cholesterol (LDL-C) and cannot meet the treatment needs of patients with familial hypercholesterolemia.
To develop a nitrogen-containing heterocyclic PCSK9 small molecule inhibitor of general formula (I) that reduces LDL-C levels via oral administration, binds to the low-density lipoprotein receptor (LDLR) on the surface of hepatocytes to block the action of PCSK9, and optimizes cholesterol homeostasis.
This invention provides an orally administered PCSK9 small molecule inhibitor that significantly reduces LDL-C levels, overcomes the side effects of statins, and is suitable for patients with familial hypercholesterolemia, reducing cardiovascular risk.